Quantitative analysis for Kyverna Therapeutics, Inc. (KYTX) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Hold (54.0) (grade C). Gem alpha score: 38.0. 30 signals analyzed (25 differentiated alt-data).
KYTX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $8.76 | $8.25 | $8.40 |
| 2026-05-11 | $10.71 | $9.37 | $10.34 |
| 2026-05-21 | $9.00 | $8.36 | $8.90 |
| 2026-06-03 | $8.13 | $7.70 | $7.82 |
| 2026-06-15 | $8.36 | $8.02 | $8.15 |
| 2026-06-26 | $8.54 | $8.05 | $8.44 |
| 2026-07-09 | $10.19 | $9.64 | $9.81 |
| 2026-07-21 | $7.52 | $7.15 | $7.48 |
| 2026-07-31 | $7.61 | $7.13 | $7.30 |
| 2026-08-12 | $8.66 | $7.78 | $8.05 |
| 2026-08-24 | $8.40 | $8.00 | $8.24 |
| 2026-09-03 | $8.78 | $8.28 | $8.35 |
How Kyverna Therapeutics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| SNDL | SNDL Inc. | $373M | — |
| IRD | Opus Genetics, Inc. | $361M | 40.0 |
| SY | So-Young International Inc. | $346M | 65.0 |
| ASMB | Assembly Biosciences, Inc. | $417M | — |
View all Health Care stocks by valuation and signals →
Kyverna Therapeutics, Inc. (KYTX) scores Hold (54.0), and the composite conceals a 61-point disagreement between its dimensions. It is strongest on competitive moat at 87 and ML forecast at 79, and weakest on technicals at 34 and AI Alpha (gem) at 26. A stock can carry competitive moat that high while AI Alpha (gem) sits at 26; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 87 |
| ML forecast | 79 |
| analyst consensus | 66 |
| technicals | 34 |
| AI Alpha (gem) | 26 |
StoQuant analyzes 30 signals (25 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Kyverna Therapeutics, Inc. (KYTX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/KYTX"><img src="https://stoquant.com/badge/KYTX.svg" alt="Kyverna Therapeutics, Inc. (KYTX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.